Bei Akademie registrieren
Recordati, IT0003828271

Recordati stock pre-market at EUR 53.98: pharma group before Xetra open

Published on 10/26/2026 at 08:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The group develops and commercializes medicines for common and rare diseases. At Lang & Schwarz the stock trades pre-market at EUR 53.98 on October 26, 2026.

Medicines and market reach

  • Recordati develops and commercializes medicines for common and rare diseases.
  • The company operates in around 150 countries.
  • Recordati stock trades pre-market at EUR 53.98 at 8:06 a.m. CET at Lang & Schwarz on October 26, 2026.
Pop-Art-Comic-Illustration eines Wissenschaftlers, der eine große Kapsel hochhält
Recordati S.p.A. (IT0003828271) wird als Pharma-Unternehmen durch diese farbenfrohe Pop-Art-Comic-Illustration mit Wissenschaftler dargestellt, Illustration mit AI erstellt.

Recordati's investor-relations materials describe the company as a global pharmaceutical group that develops and commercializes medicines for common and rare diseases. At Lang & Schwarz, Recordati stock trades pre-market at EUR 53.98 at 8:06 a.m. CET on October 26, 2026.

Ahead of the Xetra open

The bid was EUR 53.55 and the ask EUR 54.40, a spread of 1.57 percent. The further course from the Xetra open at 9:00 a.m. CET is shown by the continuously updated real-time quote of Recordati stock.

How Recordati makes its money

Recordati earns revenue by developing and commercializing medicines for common diseases, rare diseases and consumer healthcare markets, according to its investor-relations materials. The company operates in around 150 countries. Market context: Market report FTSE MIB.

More news and analysis on Recordati stock

Disclaimer...
en | IT0003828271 | RECORDATI | boerse | 70412537 | bgmi